Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).

Inclusion Criteria: 1. Newly diagnosed acute leukemia(non-M3)confirmed according to the 2018 WHO classification criteria for the diagnosis and classification of acute leukemia; 2. Suitable for standard chemotherapy regimens containing idarubicin/daunorubicin; 3. Patients with an expected survival time of at least 3 months as determined by the investigator; 4. Voluntarily agree to participate in this study and sign the informed consent form. Exclusion Criteria: 1. History of other malignant tumors concurrently or previously diagnosed malignancies not under control; 2. Participation in other clinical trials within one month prior to screening; 3. Presence of uncontrolled cerebrovascular diseases, coagulation disorders, connective tissue diseases, or other such conditions; 4. Other uncontrolled diseases that the investigator considers inappropriate for inclusion; 5. Patients with psychiatric disorders or other known or suspected inability to fully comply with the study protocol; 6. Pregnant or breastfeeding women; 7. History of liver cirrhosis, or current active liver disease or biliary disease; 8. HIV-positive individuals; 9. Any other conditions that, in the investigator's judgment, may prevent the subject from completing the study or pose significant risk to the subject.